Patent US4522804A successfully refreshed from Google Patents.
US4522804A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Constant release rate solid oral dosage formulations of propranolol
Assignee: Verex Laboratories Inc
•
Filing: 1984-02-16
•
Granted: 1985-06-11
•
Expires: 2004-02-16
Abstract
Abstract A constant order release rate solid oral dosage formulation of propranolol or a pharmaceutically acceptable salt thereof, said formulation comprising: a therapeutically effective amount of propranolol or a pharmaceutically acceptable salt; from about 0.5 to 6.0 weight percent of an acid-retardant or hydrophobic cellulose derivative; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil: from about 1 to 20 weight percent of an acrylic acid polymer; from about 0.5 to 4.0 weight percent of fumed silicon dioxide and from about 0.4 to 3.0 percent of a lubricant.
Inventors
- 👤 James M. Dunn
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 15:15
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/275; A61K9/00; A61K9/20; A61K9/2004; A61K9/2009; A61K9/2013; A61K9/2022; A61K9/2027; A61K9/205; A61K9/2054
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
99 words
A constant order release rate solid oral dosage formulation of propranolol or a pharmaceutically acceptable salt thereof, said formulation comprising: a therapeutically effective amount of propranolol or pharmaceutically acceptable salt thereof, from about 0.5 to 6.0 weight percent of microcrystalline cellulose alone or with one or more acid-retardant hydrophobic cellulose derivatives; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil; from about 1 to 20 weight percent of pharmaceutically acceptable acrylic acid polymer; from about 0.5 to 4.0 weight percent of fumed silicon dioxide and from about 0.4 to 3.0 weight percent of a tableting lubricant.
Claim 2
Dependent Claim
99 words
A constant order release rate solid oral dosage formulation of propranolol or a pharmaceutically acceptable salt thereof, said formulation comprising: a therapeutically effective amount of propranolol or pharmaceutically acceptable salt thereof, from about 0.5 to 6.0 weight percent of microcrystalline cellulose alone or with one or more acid-retardant hydrophobic cellulose derivatives; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil; from about 1 to 20 weight percent of pharmaceutically acceptable acrylic acid polymer; from about 0.5 to 4.0 weight percent of fumed silicon dioxide and from about 0.4 to 3.0 weight percent of a tableting lubricant.
Claim 3
Dependent Claim
15 words
The formulation of claim 1 wherein said acid retardant cellulose derivative is cellulose acetate phthalate.
Claim 4
Dependent Claim
14 words
The formulation of claim 1 wherein said hydrogenated vegetable oil is hydrogenated cottonseed oil.
Claim 5
Dependent Claim
13 words
The formulation of claim 1 wherein said acrylic acid polymer is carboxypolymethylene carbomer.
Claim 6
Dependent Claim
24 words
The formulation of claim 1 wherein said acid retardant cellulose derivative is cellulose acetate phthalate, and said hydrogenated vegetable oil is hydrogenated cottonseed oil.
References Cited (Backward Citations)
US3400197A
Cited
US3577514A
Cited
GB1538123A
Cited
US4138475A
Cited
US4153677A
Cited
US4248856A
Cited
US4248858A
Cited
US4248857A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-06-10 | 1988-12-10 | 1989-06-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-06-10 | 1992-12-10 | 1993-06-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-06-10 | 1996-12-10 | 1997-06-11 | $7700.00 | Window Closed / Lapsed |